65,437 trials
Triple Negative Breast Cancer · Pancreatic Carcinoma · Melanoma
Primary: Phase Ib: Percentage of Participants With Adverse Events, as a Measure of Safety — 6; 12; 12; 13 Participants
Cataract
Primary: Number of Participants Who Have Spectacle Independence — 27 Participants
Alcohol Use
Primary: Enrollment Rate — 6.25 average participants per week
Alzheimer Disease · Dementia · Cognitive Decline
Primary: Executive Function (EF). — 1.16; 0.99 z score
Osteoarthritis, Knee
Primary: Total Blood Loss After Operation — 678; 733 ml — p=0.276
Ovarian Cancer · Ovarian Neoplasms
Primary: Safety: Incidence of Post Chemotherapy Surgical Debulking — 15 Participants
Stroke
Primary: Ability of Dressing and Bathing — 0.71; 0.96 score on a scale — p=0.05
Sexual Dysfunction, Physiological
Primary: Proportion of Participants With Increased Female Sexual Function Index Lubrication Domain (FSFI-LD) Scores — 57; 43 Participants
Anesthetic Gas Consumption and Cost-Effectiveness
Primary: Primary Study Variable: Amount of Gas Vaporized Anesthetic Per Minute Anesthesia — 95.48; 119.3 grams/minute
Pneumococcal Infections
Primary: Persistence of Humoral Immunity Following PCV10 Vaccination — 0.32; 0.35 micrograms per ml
Metastatic Castration-Resistant Prostate Cancer
Primary: For Dose Escalation: Incidence of Dose-limiting Toxicities (DLT) to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ZEN003694 in…
Acute Myeloid Leukemia
Primary: Time to Relapse (TTR) — 12.14 months
Epilepsy
Primary: Maximum Observed Change From Pretreatment Baseline in the Standardized Photosensitivity Range (SPR) — -0.2; -4.4; -5.2; -4.8 Number of frequency steps
Dementia · Infection, Bacterial
Primary: Total Antimicrobial Use for LRI and UTIs — 0.55; 0.82 antimicrobial courses per person-year
Bladder Cancer
Primary: Percentage of Subjects That Reach Pathological Downstaging (Response) at the Time of Cystectomy — 56 percentage of patients with response